Maxygen, Inc.

Dna Twopointo Inc.

Codexis Mayflower Holdings, LLC

Archer Daniels Midland Company

Butamax Advanced Biofuels LLC

Stichting Sanquin Bloedvoorziening

Othair Prothena Limited

Allena Pharmaceuticals, Inc.

Gemini Therapeutics Sub, Inc.

Neptune Biosciences LLC

Repligen Corporation

Sridhar Govindarajan

Jeremy S Minshull

Claes Gustafsson

Phillip A Patten

Robin A Emig

Richard John Fox

Torben Lauesgaard Nissen

Maggie Lee

Sridhar Viswanathan

Linda A Castle

S Christopher Davis

Rebecca Lynne Gorton

Daniel Siehl

Anthony Cox

Teddy Chen

Ajoy K Roy

Mark D Welch

Jon Edward Ness

Emily C Mundorff

Daniel P O'Keefe

Yougen Li

William Schroeder

Padmesh Venkitasubramanian

Steven Cary Rothman

Der-Ing Liao

Tom Purcell

Alexander Vincent Tobias

Guy Cavet

Robin McDaid Barbour

Tarlochan S Nijjar

Benedikt K Vollrath

Wagner Marcelo Zago

Frédérique Bard

Danica Grujic

Nicolay V Kulikov

Taco Willem Kuijpers

Michael Skov

Maria Clara Brouwer

Richard Benjamin Pouw

Diana Wouters

Ilse Jongerius

Daniel L Siehl

Scott Lauder

Taede Rispens

Gillian Dekkers

Nigel Killeen

Oren Beske

Aditi R Deshpande

Alan Marco Villalobos

Will Schroeder

Phil Patten

Jon E Ness

Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.

Anti-Aβ antibodies

The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.

Transposition of nucleic acids into eukaryotic genomes with a transposase from heliothis

Orthogonal IL-21 receptors and orthogonal IL-21 cytokines are described. The IL-21 receptor-cytokine pairs may include an orthogonal interleukin-21 receptor α chain ('ortho-IL-21Rα') that has impaired binding to native interleukin-21 cytokine (“IL-21”) and an orthogonal IL-21 cytokine (“ortho-IL-21”) that has impaired binding to native IL-21Rα, wherein the ortho-IL-21Rα binds to the ortho-IL-21. The IL-21 receptor-cytokine pair may activate IL-21 signaling. Cells engineered to express the orthogonal IL-21 receptors are also described, as well as methods for using such cells for treatment of various diseases and disorders.

Engineered human IL-21 cytokines and methods for using the same

This disclosure provides epimerase enzymes useful for commercial scale production of allulose from fructose. The disclosed enzymes ('epimerase variants') are variants ofCGD1 xylose isomerase engineered to have improved catalytic activity of about 1.5- to 2-fold compared with the parent enzyme.

Epimerase enzymes and their use

Provided herein are novel isolated, synthetic or recombinant antibodies and fragments thereof specific for factor H, or nucleic acids or vectors encoding such antibodies and fragments. Further provided herein is the use of such antibodies, fragments, nucleic acids or vectors for inhibiting complement activation and treatment of disorders associated with complement activation.

Factor H potentiating antibodies and uses thereof

Integration of nucleic acid constructs into eukaryotic cells with a transposase from oryzias

Transposition of nucleic acid constructs into eukaryotic genomes with a transposase from amyelois

Disclosed are recombinant mutanturicase enzymes with improved pancreatin stability and/or activity, compositions containing such uricase enzymes, which can be used, among other things, to treat diseases or disorders associated with an elevated amount of uric acid, including, for example, hyperuricemia, hyperuricosuria, and gout.

Recombinant uricase enzyme

Disclosed herein are three geneses of proteins herein established to exhibit a fructose to allulose epimerase activity that are useful for production of allulose from fructose at high temperatures and at low pH in the range of 4.5 to 6.0. Two of the three geneses descend phylogenetically from a common ancestral protein defined herein, and these geneses are distinguished from each other by different parental descendant proteins also defined herein. The proteins with high levels of sequence identity to the parental nodes defining from these two geneses generally exhibit higher levels of specific fructose to glucose epimerase activity than prior known fructose to allulose epimerases and exhibit such activity at low pH. A third genus is not defined by phylogenetic origin except by not descending from the same ancestor as the first two geneses but generally exhibit similar levels of fructose to allulose epimerase activities as prior art epimerases described to be useful for fructose to allulose conversion.

Genus of epimerase enzymes for conversion of fructose to allulose at high temperature and low pH

The present invention generally relates to methods of rapidly and efficiently searching biologically-related data space. More specifically, the invention includes methods of identifying bio-molecules with desired properties, or which are most suitable for acquiring such properties, from complex bio-molecule libraries or sets of such libraries. The invention also provides methods of modeling sequence-activity relationships. As many of the methods are computer-implemented, the invention additionally provides digital systems and software for performing these methods.

Methods, systems, and software for identifying functional bio-molecules

Provided herein are polypeptides having ketol-acid reductoisomerase activity as well as microbial host cells comprising such polypeptides. Polypeptides provided herein may be used in biosynthetic pathways, including, but not limited to, isobutanol biosynthetic pathways.

Ketol-acid reductoisomerase enzymes and methods of use

Provided herein are polypeptides having ketol-aid reductoisomerase activity as well as microbial host cells comprising such polypeptides. Polypeptides provided herein may be used in biosynthetic pathways, including, but not limited to, isobutanol biosynthetic pathways.

Growing community of inventors

Redwood City, CA, United States of America

Sridhar Govindarajan